LONDON (Alliance News) - Physiomics PLC Monday said it has signed a contract with a new speciality pharmaceuticals customer to investigate how one of the client's new candidate drugs shrinks tumours.
Physiomics scientists will use systems biology approaches to map the possible pathways by which the drug could act, it said in a statement without giving any financial details. The analysis will be used to narrow down possible mechanisms and suggest new experiments that the client can perform to home in on one mechanism.
"If successful, the directors hope that Physiomics will be able to offer its other modelling services to this new client as the project progresses," the company said in a statement.
Physiomics shares were up 31.6% at 0.25 pence early Monday, the biggest gainer on AIM.
By Steve McGrath; stevemcgrath@alliancenews.com; @SteveMcGrath1
Copyright 2013 Alliance News Limited. All Rights Reserved.


(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Wednesday and not separately reported...


(Sharecast News) - Physiomics said on Friday that it was making strong operational progress and building the largest commercial pipeline in its histor...


(Sharecast News) - Physiomics said on Friday that it was making strong operational progress and building the largest commercial pipeline in its histor...


IN BRIEF: Physiomics Annual Revenue Grows And Loss Narrows


UK TRADING UPDATE SUMMARY: Brickability Recovering Well From Pandemic


(Sharecast News) - Oncology consultancy Physiomics announced on Friday that it has been awarded a contract by a new client, Japan-based global pharmac...


IN BRIEF: Physiomics Has No Explanation For Share Price Surge


Physiomics Raises New Funds To "Further Develop Its Business"


(Sharecast News) - Oncology consultancy Physiomics has raised roughly £829,000 through a share issue to finance further development.


Physiomics Secures Additional Contract With Bicycle Therapeutics


Physiomics Believes Strong Pipeline Can Withstand Covid-19 Oubtreak